UK Government Invests in Visiopharm, Increasing Access to Ground-Breaking Digital Pathology in the NHS

December 2nd, 2019

The Danish-based leader in augmented pathology solutions Visiopharm has secured a grant worth £250,000 from UK Research and Innovation to test its innovative solutions in partnership with the NHS.

The grant, offered by the UK Government’s innovations fund, was offered specifically to boost SMEs offering support to evaluate an innovative medical technology.

Read more

Visiopharm Celebrates the Opening of Its New DACH Subsidiary in Germany

May 28th, 2019

Danish-based leader in augmented pathology solutions Visiopharm has opened a new subsidiary in Germany to serve as the company’s headquarters in the DACH region.

The German office allows Visiopharm to meet its customers’ needs in an agile fashion and will be focused on driving business in the pharmaceutical and academic research fields, while further translating it into the healthcare and diagnostics sphere. 

Read more

OracleBio incorporates Artificial Intelligence (AI) Deep Learning and High Multiplex Image Analysis Technologies to enhance Digital Pathology Capabilities

May 16th, 2019

OracleBio Limited is pleased to announce the integration of Visiopharm’s Artificial Intelligence (AI) deep learning and phenotyping multiplexing modules into its existing Oncotopix® image analysis platform.

The Oncotopix® AI deep learning module allows OracleBio to access a range of the most up-to-date deep convolution neural networks for a more precise and robust classification of objects or regions of interest in tissue-based images. For example, these can include cell types, tumour regions, glomeruli, brain regions or any unique object or region.

Read more

Visiopharm Welcomes Adrian Arechiga Arechiga as Chief Marketing Officer 

May 16th, 2019

Visiopharm is delighted to announce Adrian Arechiga Ph.D. as its new Chief Marketing Officer. Highly experienced as a Senior Marketing Director, Adrian has an impressive track record of working internationally in the biopharma, oncology diagnostics, and life science industries.

Adrian will be instrumental in leading Visiopharm’s marketing through its expansion following significant investment. He will be based in Visiopharm’s new office in Germany. 

Read more